Yet Another Myeloma CAR-T Therapy Makes It Onto EMA’s PRIME

Another investigational Chikungunya vaccine has also entered PRIME

Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.

Motorbike
Developing drugs under PRIME can help companies get to market faster • Source: Shutterstock

Another CAR-T therapy for treating multiple myeloma and a Chikungunya virus vaccine are the latest investigational products to secure a hard-to-obtain place on the European Medicines Agency’s PRIME scheme for getting treatments for unmet medical need to patients faster.

CT053, the CAR-T therapy that CARsgen Therapeutics is developing, and Emergent BioSolutions’s CHIKV virus-like particle (VLP) were both...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography